AU2003227919A1 - Dopamine receptor modulators as antipsychotic agents - Google Patents

Dopamine receptor modulators as antipsychotic agents

Info

Publication number
AU2003227919A1
AU2003227919A1 AU2003227919A AU2003227919A AU2003227919A1 AU 2003227919 A1 AU2003227919 A1 AU 2003227919A1 AU 2003227919 A AU2003227919 A AU 2003227919A AU 2003227919 A AU2003227919 A AU 2003227919A AU 2003227919 A1 AU2003227919 A1 AU 2003227919A1
Authority
AU
Australia
Prior art keywords
receptor modulators
dopamine receptor
antipsychotic agents
antipsychotic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003227919A
Other languages
English (en)
Inventor
David Gwyn Cooper
Ian Thomson Forbes
Andrew Derrick Gribble
Andrew Lightfoot
Andrew H. Payne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2003227919A1 publication Critical patent/AU2003227919A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AU2003227919A 2002-05-10 2003-05-09 Dopamine receptor modulators as antipsychotic agents Abandoned AU2003227919A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0210762.1 2002-05-10
GBGB0210762.1A GB0210762D0 (en) 2002-05-10 2002-05-10 Compounds
PCT/GB2003/001983 WO2003095428A1 (en) 2002-05-10 2003-05-09 Dopamine receptor modulators as antipsychotic agents

Publications (1)

Publication Number Publication Date
AU2003227919A1 true AU2003227919A1 (en) 2003-11-11

Family

ID=9936447

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003227919A Abandoned AU2003227919A1 (en) 2002-05-10 2003-05-09 Dopamine receptor modulators as antipsychotic agents

Country Status (6)

Country Link
US (1) US20070043026A1 (cg-RX-API-DMAC7.html)
EP (1) EP1503989A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005532318A (cg-RX-API-DMAC7.html)
AU (1) AU2003227919A1 (cg-RX-API-DMAC7.html)
GB (1) GB0210762D0 (cg-RX-API-DMAC7.html)
WO (1) WO2003095428A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY133587A (en) 2002-05-29 2007-11-30 Glaxo Group Ltd Aromatic sulfones and their medical use
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
US20050137186A1 (en) * 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
US8207160B2 (en) 2003-12-18 2012-06-26 Abbott Gmbh & Co. Kg Tetrahydrobenzazepines and their use in he modulation of the dopamine D3 receptor
TW200611701A (en) * 2004-06-18 2006-04-16 Glaxo Group Ltd Novel compounds
EP2371814A1 (en) * 2004-10-14 2011-10-05 Abbott GmbH & Co. KG Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
EP1837332A1 (en) * 2006-03-23 2007-09-26 Laboratorios Del Dr. Esteve, S.A. Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
US7897595B2 (en) 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
US8258134B2 (en) * 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321254A (en) * 1980-09-26 1982-03-23 Smithkline Corporation Antiallergic imidodisulfamides
US5112824A (en) * 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
US5684195A (en) * 1994-07-14 1997-11-04 G. D. Searle & Co. Method of preparing sulfmonamides from sulfones
NZ332757A (en) * 1996-06-17 1999-06-29 Smithkline Beecham Plc Substituted tetrahydroisoquinoline benzamide derivatives and their use as anticonvulsants and psycho-active agents
IL131756A0 (en) * 1997-03-18 2001-03-19 Smithkline Beecham Plc Substituted isoquinoline derivatives and their use as anticonvulsants
JP2001521026A (ja) * 1997-10-24 2001-11-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 置換イソキノリン誘導体および抗痙攣薬としての使用
DE10053799A1 (de) * 2000-10-30 2002-05-08 Bayer Ag Verwendung von Tetrahydroisochinolinsulfonamiden

Also Published As

Publication number Publication date
JP2005532318A (ja) 2005-10-27
WO2003095428A1 (en) 2003-11-20
US20070043026A1 (en) 2007-02-22
EP1503989A1 (en) 2005-02-09
GB0210762D0 (en) 2002-06-19

Similar Documents

Publication Publication Date Title
AU2003253535A1 (en) N-4-piperidinyl compounds as ccr5 modulators
AU2003290700A1 (en) Farnesoid x receptor agonists
EP1569685B8 (en) Complement receptor 2 targeted complement modulators
AU2003241836A1 (en) Lpa receptor antagonists
AU2003212708A1 (en) Baculovirus expression system
AU2003259482A1 (en) N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
AU2003277576A1 (en) Receptor function controlling agent
ZA200604778B (en) Azabicyclic heterocycles as cannabinoid receptor modulators
IL164261A0 (en) Tropane derivatives as ccr5 modulators
AU2003266267A1 (en) Birefringent marking
AU2003275838A1 (en) Pyrrolidin-2-on derivatives as ep4 receptor agonists
AU2003219814A1 (en) Release agents
AU2003256922A1 (en) Substituted heterocyclic compounds as modulators of the ccr5 receptor
PL371344A1 (en) Benzenesulfonamide derivatives as antipsychotic agents
AU2002335075A1 (en) Estrogen receptor modulators
AU2003301299A1 (en) Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
AU2002347552A1 (en) 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU2003231523A1 (en) Estrogen receptor modulators
AU2003293495A1 (en) 2-aryl thiazole derivatives as kcnq modulators
AU2003251627A1 (en) Carvedilol hydrobromide
AU2003274836A1 (en) Compensation device
AU2003227449A1 (en) Demultiplexing device
AU2003244148A1 (en) Antifungal agents for external use
AU2003302405A1 (en) T-cell receptors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 18, NO 2, PAGE(S) 542 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAMES FORBES, I.; LIGHTFOOT, A.; PAYNE, A.; GLAXO GROUP LIMITE; GRIBBLE, A. AND COOPER, D., APPLICATION NO. 2003227919, UNDER INID (43) CORRECT THE PUBLICATION DATE TO READ 24.11.2003